. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: Mol Diagn Ther. 2013 Jun;17(3):139–146. doi: 10.1007/s40291-013-0027-6

Table 1.

Multiplex biomarker panels which discriminate ovarian cancer from healthy controls.

Panel	Cases/ Controls	SN/SP	Analytical platform	Year/Ref
CA 125, ApoA1, TTR	118/61	93.9/95	BBIA	2012/²³
CA 125, HE4, CEA, VCAM-1	456/2000^†	86-93/98	BBIA	2010/²²
CA 125, CRP, SAA, IL6, IL8	150/212^†	94.1/91.3	BBIA	2010/²⁷
CA-125, CA 19-9, EGFR, CRP, myoglobin, Apo A1, Apo CIII, MIP1a, IL6, IL18, tenascin C	176/187^†	91.3/88.5	BBIA	2009/²⁸
CA 125, leptin, PRL, OPN, IGFII, MIF	156/362^†	95.3/99.4	MS/ELISA	2008/¹⁹
CA 125, TTR, ApoA1, TF	126/82	89/92	MS	2007/²⁵
CA 125, ApoA1, TTR	200/142^†	74/97	MS	2004/²⁴
CA 125, HE4, SI^*	74/137^‡	84/98.5	ELISA	2010/³¹
CA 125, CA 72-4, CA 15-3, MCSF	123/224^†	70/98	ELISA	2004/²⁶

Symptom index;

^†

includes independent validation set;

^‡

prediagnostic samples; BBIA-bead-based immunoassay; MS – mass spectroscopy